The Biotech Bull Market Is Back

LAS VEGAS, NV / ACCESSWIRE / March 9, 2016 / In 2012 the NYSE Biotechnology Index began a climb, this bull market went nearly unimpeded from $1000 a share in 2012 to nearly $4400 a share by July of 2015. That's when biotech as a part of the larger indexes began to make a bearish turn, then in February the market began to make a recovery. The NYSE Biotechnology Index in particular has bounced hard off of a long term uptrend line.

As a result the market is littered with enticing profit opportunities in biotech, and several of them have already started to make their move so investors looking to benefit from this run need to act soon!

Here's some of the best opportunities we see on capitalizing on the biotech recovery:

Endonovo Therapeutics, Inc. (ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced it has retained Holland & Knight to prepare and file the paperwork necessary to obtain an orphan drug designation for Endonovo's proprietary Cytotronicsâ„¢ product.

Endonovo is requesting the orphan drug designation for its next-generation, off-the-shelf treatment of Graft-Versus-Host Disease (GVHD) using Cytotronicsâ„¢ expanded and ex vivo enhanced stem cells from the human umbilical cord.

If Endonovo receives FDA approval to market its product for this indication the Company could immediately reach a billion dollar valuation! To put that in perspective, ENDV's current market cap is $39.5 million. So needless to say, though I will anyway, a $960 million dollar climb in valuation would be a pretty big deal. We're already seeing investors snatch up their tickets for this ride, the 38 cent stock has climbed over 10 cents a share in the past few weeks, but judging by its move earlier this year, as well as the aforementioned news, there's still plenty of headroom on the chart for this stock.

Investors should consider acting quickly on this fast moving opportunity.

BioCryst Pharmaceuticals (BCRX) , which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BCRX is probably the poster child for the biotech rebound, after being destroyed by the bears over the last six months, with shares plunging lower by 81.7%, the stock has gained over a dollar a share reaching a high of $2.51 as of press time.

PTC Therapeutics' (PTCT) move on Wednesday could have just been a technical correction, but the size of the move is too much for traders to ignore. PTCT shares had been slide with the company being hit by a series of setbacks. While the major setback for the company was the FDA's "Refusal to File" letter for the company's regulatory application for its experimental Duchenne muscular dystrophy (DMD) treatment, Translarna, the company faced another setback related to the pricing and reimbursement of Translarna in Germany.

Translarna, which is approved in the European Economic Area (EEA), is commercially available in Germany since Dec 2014. However, with pricing and reimbursement discussions not ending on a satisfactory note, PTC is thinking of delisting Translarna from the German pharmacy ordering system. The volatility alone makes PTCT at least worth monitoring.

Geron Corporation (GERN) has put all of its weight behind developing a single drug following its restructuring process that started in 2011. This drug is a telomerase inhibitor called imetelstat that has the potential to be a truly disease-modifying treatment for deadly blood disorders such as myelofibrosis and myelodysplastic syndrome. Despite some rough financial reports recently continues to earn investors as it fights to reward them for taking the risk.

ImmunoCellular Therapeutics, Ltd. (IMUC) announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors (TCRs) developed in the laboratory of Prof. Mark Davis, Director, Stanford Institute for Immunity, Transplantation and Infection, and The Burt and Marion Avery Family Professor of Immunology at Stanford University School of Medicine. This news has been received favorably by investors sending the stock from 24 cents a share to a high of 32.

With the biotech market looking bullish again, there are exciting opportunities all over the industry for investors. From our scans, we think ENDV may offer investors the highest profit potential, make sure to act soon to secure your piece of the biotech profit pie!

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $16,000 cash by a non-affiliate third party of ENDV.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.